1,537 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AMGN Amgen Inc. $200.81 $129.98B Uptrend
Article Searches
BeyondSpring's lead candidate on par with Amgen's Neulasta in late-stage study; shares ahead 3% https://seekingalpha.com/news/3414993-beyondsprings-lead-candidate-par-amgens-neulasta-late-stage-study-shares-ahead-3-percent?source=feed_news_all Dec 06, 2018 - Ultra-thinly traded BeyondSpring (BYSI +3.2%) is up on almost double normal volume, albeit on turnover of only 12K shares, on the heels of its announcement of positive results evaluating lead candidat
Spectrum Pharma's Rolontis on par with Amgen's Neulasta in late-stage breast cancer study https://seekingalpha.com/news/3414951-spectrum-pharmas-rolontis-par-amgens-neulasta-late-stage-breast-cancer-study?source=feed_news_all Dec 06, 2018 - Results from a Phase 3 clinical trial, RECOVER, evaluating Spectrum Pharmaceuticals' (SPPI -2.4%) ROLONTIS (eflapegrastim) for reducing the duration of severe neutropenia (low levels of a type of whit
Amgen Tour of California to end with Santa Clarita-to-Pasadena finish https://www.ocregister.com/2018/12/05/amgen-tour-of-california-to-end-with-santa-clarita-to-pasadena-finish/ Dec 05, 2018 - The 14th edition of the Amgen Tour of California will include a stage running from Ontario to Mt. Baldy and will finish in Pasadena.
Biotech Stock Roundup: ASH Meet in Focus, Gilead's Drugs Get Approval in China http://www.zacks.com/stock/news/341263/biotech-stock-roundup-ash-meet-in-focus-gileads-drugs-get-approval-in-china?cid=CS-ZC-FT-341263 Dec 05, 2018 - This week, focus was on data presented at the annual conference of the American Society of Hematology from Dec 1-4. Apart from this, the regular pipeline updates were also in focus in the biotech sector.
Amgen Tour of California announces dates and host cities for 2019 races http://www.latimes.com/sports/la-sp-tour-of-california-20181204-story.html Dec 05, 2018 -

The 14th edition of the Amgen Tour of California cycling race will start in Sacramento on May 12 and work its way down to the finish line in Pasadena on May 18, covering more than 750 miles over seven stages.

The course and the dates for the men’s and women’s events were announced by event organizers...

Amgen Tour of California to end with Santa Clarita-to-Pasadena finish https://www.ocregister.com/2018/12/04/amgen-tour-of-california-to-end-with-santa-clarita-to-pasadena-finish/ Dec 04, 2018 - The 14th edition of the Amgen Tour of California will include a stage running from Ontario to Mt. Baldy and will finish in Pasadena.
Amgen Can Offer Total Returns Of Nearly 10% Per Year https://seekingalpha.com/article/4226213-amgen-can-offer-total-returns-nearly-10-percent-per-year?source=feed_sector_healthcare Dec 04, 2018 - Amgen is a relatively new dividend payer, with 8 years of annual dividend increases. But the dividend has room to grow at a high rate moving forward. New products such as Repatha and Prolia will lead
AbbVie Settles With Pfizer for Humira Biosimilar in U.S. http://www.zacks.com/stock/news/340832/abbvie-settles-with-pfizer-for-humira-biosimilar-in-us?cid=CS-ZC-FT-340832 Dec 03, 2018 - AbbVie (ABBV) strikes a deal with Pfizer to launch its biosimilar of Humira in the United States in November
Synthorx Files Proposed Terms For U.S. IPO https://seekingalpha.com/article/4225412-synthorx-files-proposed-terms-u-s-ipo?source=feed_tag_ipo_analysis Nov 29, 2018 - Synthorx intends to raise $100 million from the sale of its common stock.The firm is advancing a pipeline of treatment candidates for various cancers and autoimmune diseases.THOR has strong support fr
FDA Ad Com January 16 for Amgen's osteoporosis med romosozumab https://seekingalpha.com/news/3413186-fda-ad-com-january-16-amgens-osteoporosis-med-romosozumab?source=feed_news_all Nov 29, 2018 - The FDA's Reproductive and Urologic Drugs Advisory Committee will meet on Wednesday, January 16, 2019, to review and discuss Amgen's (AMGN -0.4%) resubmitted marketing application seeking approval fo

Pages: 123456...154

Page 1>

Related Companies

Name Exchange Price Mkt Cap
GILD Gilead Sciences, Inc. NASDAQ $72.78 $94.35B
BIIB Biogen Inc. NASDAQ $334.44 $67.37B
SGEN Seattle Genetics, Inc. NASDAQ $76.15 $12.09B
NBIX Neurocrine Biosciences, Inc. NASDAQ $117.38 $10.62B
QGEN Qiagen N.V. NASDAQ $37.42 $8.5B
Sector: Health Care > Industry: Biotechnology: Biological Products (No Diagnostic Substances)
DeepLinks for Amgen
AMGN - Google Finance https://www.google.com/finance?q=AMGN Industry related info and international coverage Summary News
AMGN - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=AMGN Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options